Hydrogen Sulfide SIBO Explained: The Third Type of SIBO Most People Have Never Heard Of

For years, SIBO was understood as a two-gas problem: hydrogen-dominant and methane-dominant (now called intestinal methanogen overgrowth, or IMO). Patients were tested with breath tests that measured only these two gases. If both came back low, the test was called negative and SIBO was considered ruled out. But a significant number of those 'negative' patients still had all the symptoms of bacterial overgrowth. The missing piece was hydrogen sulfide. Hydrogen sulfide SIBO, driven by sulfate-reducing bacteria, represents the third type of small intestinal bacterial overgrowth. It has its own distinctive symptom profile, its own diagnostic challenges, and its own treatment requirements. Understanding it changes the diagnostic picture for a large population of patients who have been told they do not have SIBO when they actually do.

What is hydrogen sulfide SIBO?

Hydrogen sulfide (H2S) SIBO occurs when sulfate-reducing bacteria (SRB) overgrow in the small intestine and produce excessive hydrogen sulfide gas. These bacteria have a unique metabolism: they use hydrogen gas as an energy source and sulfate (from dietary sulfur compounds) as an electron acceptor, producing H2S as a metabolic waste product. This means SRB are dependent on hydrogen-producing bacteria to provide their fuel. In a typical H2S SIBO ecosystem, fermentative bacteria break down carbohydrates and produce hydrogen, and sulfate-reducing bacteria immediately consume that hydrogen and convert it to hydrogen sulfide. This metabolic relationship explains the characteristic flat-line hydrogen pattern seen on standard breath tests: the hydrogen is being produced but consumed before it can reach the breath.

Why standard breath tests miss it

Standard lactulose and glucose breath tests measure hydrogen and methane in exhaled breath. They do not measure hydrogen sulfide. When a patient has H2S SIBO, the sulfate-reducing bacteria consume hydrogen as fast as it is produced, resulting in hydrogen levels that remain near baseline throughout the test. Methane may or may not be elevated, depending on whether methanogens are also present. The result is a test that appears normal or flat, leading the clinician to conclude that SIBO is not present. This is one of the most significant diagnostic blind spots in current SIBO testing. Patients with classic SIBO symptoms, who improve with dietary restriction and worsen with sulfur-rich foods, receive negative breath tests and are told their symptoms must be something else.

Distinctive symptoms of H2S SIBO

While H2S SIBO shares many symptoms with other forms of SIBO (bloating, abdominal pain, fatigue), it also produces several distinctive features that can help clinicians and patients recognize it. The most characteristic is sulfur-smelling gas and burps, often described as a rotten egg odor. This results from the H2S gas itself. Diarrhea is common and often urgent, as hydrogen sulfide stimulates chloride secretion in the colon and increases intestinal motility. Brain fog and cognitive difficulties are frequently reported and may relate to the neurotoxic effects of H2S, which crosses the blood-brain barrier. Bladder irritation and urgency are reported by some patients, potentially due to H2S effects on bladder smooth muscle. Sensitivity to sulfur-containing foods (eggs, garlic, onions, cruciferous vegetables, wine) is a pattern that many patients notice before diagnosis.

How H2S SIBO differs from hydrogen and methane types

The three types of SIBO are defined by which gas predominates, and each has a somewhat different clinical profile. Hydrogen-dominant SIBO tends toward diarrhea and is driven by fermentative bacteria like E. coli and Klebsiella. Methane-dominant SIBO (IMO) tends toward constipation and is driven by methanogenic archaea, primarily Methanobrevibacter smithii. Hydrogen sulfide SIBO tends toward diarrhea (like hydrogen-dominant) but with the added sulfur symptoms, neurological effects, and a different bacterial population (sulfate-reducing bacteria). Importantly, these types can overlap. A patient may have elevated hydrogen and hydrogen sulfide, or all three gases may be elevated. The dominant gas often determines the predominant symptom pattern but combinations are common.

The toxicity of hydrogen sulfide

Hydrogen sulfide is not merely a byproduct of bacterial metabolism. It is a biologically active molecule with significant toxic potential at elevated concentrations. At low physiological levels, H2S actually serves beneficial signaling functions in the body, including vasodilation and anti-inflammatory effects. However, at the elevated concentrations produced by sulfate-reducing bacterial overgrowth, H2S becomes cytotoxic. It inhibits cytochrome c oxidase in the mitochondrial electron transport chain, the same enzyme targeted by cyanide, effectively shutting down cellular energy production. In the gut, this manifests as damage to the intestinal epithelium, impaired mucosal barrier function, and inflammation. The systemic effects, including brain fog, fatigue, and malaise, may reflect the impact of absorbed H2S on mitochondrial function in tissues throughout the body.

Treatment approaches for H2S SIBO

Treating H2S SIBO requires strategies that target sulfate-reducing bacteria specifically, in addition to the general approaches used for other forms of SIBO. Rifaximin remains a first-line antimicrobial, but some practitioners add bismuth subsalicylate (Pepto-Bismol), which binds sulfide in the gut lumen and has direct antimicrobial activity against sulfate-reducing bacteria. Dietary sulfur restriction (reducing intake of eggs, cruciferous vegetables, alliums, and high-sulfur proteins) can reduce the substrate available to SRB, though the evidence for this approach is largely clinical rather than from controlled trials. Molybdenum supplementation has been used in some protocols to support sulfite oxidase, the enzyme that processes sulfur compounds, though evidence for this is preliminary. Addressing the underlying SIBO root causes, particularly motility dysfunction and MMC impairment, remains essential for preventing recurrence.